Bristol Myers reports 52% reduction in progression risk for next-gen multiple myeloma drug in Phase 3 trial

Bristol Myers Squibb said its next-generation multiple myeloma therapy, positioned as a successor to Pomalyst, lowered the risk of disease progression or death by 52% when added to a standard combination regimen in a Phase 3 study.

The trial result was described as a win for the company, highlighting a substantial improvement for the patient subgroup evaluated. The data suggest the new agent could become an important addition to existing treatment options for multiple myeloma.

The company did not disclose the drug’s name or further development timelines, but the positive readout is expected to support future regulatory discussions and potential market launch.